Biotechnology - Mergers & Acquisitions, Immunologicals

Filter

Popular Filters

Resverlogix to spin-out RVX Thera to unlock epigenetics platform value

10-04-2013

Canadian drugmaker Resverlogix (TSX:RVX), which is exploring a sale, says that its board of directors…

ApolipoproteinBiotechnologyImmunologicalsMergers & AcquisitionsOncologyResverlogixRVX TherapeuticsRVX-208

Aduro BioTech buys all GVAX assets from BioSante; Aspen in talks to buy Merck unit

05-02-2013

Aduro BioTech, a privately-held, US venture capital backed biotechnology company, says it has acquired…

Aduro BioTechAspen PharmacareBioSante PharmaceuticalsBiotechnologyGenericsGVAXImmunologicalsMerck & CoMergers & AcquisitionsOncologyVaccines

AstraZeneca partners with WuXi AppTec to speed novel biologic to Chinese market

11-09-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has formed a joint venture with China's WuXi AppTec to…

Anti-Arthritics/RheumaticsAsia-PacificAstraZenecaBiotechnologyImmunologicalsInflammatory diseasesMEDI5117MedImmuneMergers & AcquisitionsPharmaceuticalResearchWuXi Apptec

InterMune to divest Actimmune for $55 million; to focus on Esbriet

22-05-2012

California, USA-based biotech firm InterMune (Nasdaq: ITMN) says that it has reached a definitive agreement…

ActimmuneBiotechnologyEsbrietFinancialImmunologicalsInterMuneMergers & AcquisitionsRespiratory and PulmonaryVidara Therapeutics

Back to top